A clinical study of RP-0320
Latest Information Update: 29 Nov 2021
At a glance
- Drugs RP-0320 (Primary)
- Indications Haematological malignancies; Solid tumours
- Focus Adverse reactions
- Sponsors Penrose TherapeuTx
- 29 Nov 2021 New trial record
- 15 Nov 2021 According to a Penrose TherapeuTx media release, this study is expected to begin in 2022.